[en] The SCOPE study assesses the prevalence of anti-SARS-CoV-2 antibodies among a representative
sample of residents and staff in Belgian NH (nursing homes). Starting from February 1st 2021, a cohort
of 1,640 residents and 1.368 staff members in 69 Belgian NHs are being tested every two months on
the presence of anti-SARS-CoV-2 antibodies.
This brief communication reports on the prevalence of anti-SARS-CoV-2 antibodies among vaccinated
nursing home residents and staff. At the end of April 2021, the large scale vaccination campaign in
Belgian nursing homes, which took place between January 5th and March 24th 2021, resulted in a
vaccination coverage of 97% in NH residents and 84% in staff members. For these vaccinated groups,
we describe the prevalence of anti-SARS-CoV-2 antibodies immediately following the vaccination
campaign (April, 2021) and the seroprevalence evolution over the two following testing periods (in June
and August 2021). Data collection of the August 2021 testing period was not finished at the time of
compiling this brief communication. The August 2021 testing period comprises the data from 65 out of
the 69 nursing homes. Additionally, some antibody test results are expected the coming weeks in case
of self-sampling (for staff in particular). Results given here are preliminary. Small adaptations in some
data might occur in future reports.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Meyers, Eline
Deschepper, Ellen
Duysburgh, Els
De Rop, Liselore
De Burghgraeve, Tine
Ngoc, Pauline
Di Gregorio, Marina ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Delogne, Simon ; Université de Liège - ULiège > Master spéc. méd. gén. (nouvelle formule 3 ans)
Coen, Anja
De Clercq, Nele
Buret, Laetitia ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Coenen, Samuel
De Sutter, An
Scholtes, Béatrice ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
